Home > Dermatology > AAD 2018 > Late-breakers > IL-17C inhibition in AD and new oral treatments

IL-17C inhibition in AD and new oral treatments

Presented By
Prof. Diamant Thaçi, University Clinic Schleswig-Holstein, Germany; Prof. Emma Guttmann-Yassky, Mount Sinai Hospital, USA
AAD 2018
As in every year, the late breaker sessions were one of the main attractions of the AAD meeting. A clear focus was on the indications of atopic dermatitis and psoriasis. Biologics will play an increasingly important role in the management of these diseases. IL-17C Inhibition in AD: a new treatment approach Last autumn, the first biologic for atopic dermatitis (AD) was approved in Europe. But more is yet to come! Another interesting approach is blockade of interleukin (IL)-17C, which was shown to be remarkably effective in a randomised controlled, dose-escalation, phase-1 trial presented by Prof. Diamant Thaçi MD, University Clinic Schleswig-Holstein [1]. “In moderate-to-severe AD we have a clear unmet medical need for treatments that are safe and efficacious”, Prof. Thaci emphasised during the presentation of the data. The rationale for this trial was experimental evidence that IL-17C induces expression of proinflammatory cyto...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on